INT33518

Context Info Confidence 0.39 First Reported 1985 Last Reported 2008 Negated 0 Speculated 0 Reported most in Body Documents 2 Total Number 2 Disease Relevance 0.14 Pain Relevance 0.41

cell proliferation (PRL) cytosol (PRL) extracellular region (PRL)

Anatomy Link Frequency plasma 2 PRL (Homo sapiens)

Pain Link Frequency Relevance Heat narcan 1 99.90 antagonist 1 99.72 opioid receptor 2 99.50 Opioid 4 80.76 Somatostatin 5 5.00 Neurotransmitter 2 5.00 depression 1 5.00 Dopamine 1 5.00 headache 1 5.00 Electroencephalography 1 5.00

Disease Link Frequency Relevance Heat Acromegaly 7 75.16 Disease 3 62.48 Adenoma 14 5.00 Thyroid Disease 13 5.00 Pituitary Cancer 11 5.00 Cancer 9 5.00 Congenital Anomalies 4 5.00 Prolactinoma 3 5.00 Obesity 3 5.00 Thyroid Hormone Resistance Syndrome 3 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Pretreatment with the opioid receptor antagonist naloxone (N) suppressed the PRL and TSH response to D, blunted the D-induced GH and PRA increase, and completely prevented the D-induced plasma cortisol decrease, but enhanced plasma cortisol and ACTH levels.

Negative_regulation (suppressed) of Regulation (response) of PRL in plasma associated with antagonist, narcan and opioid receptor

1) Confidence 0.39 Published 1985 Journal Peptides Section Abstract Doc Link 3008118 Disease Relevance 0 Pain Relevance 0.41

The regularity of PRL patterns in patients was diminished compared with controls, as defined by higher ApEn ratios in patients (0.788 ± 0.074, mean ± SD) than controls (0.461 ± 0.131, P < 0.001).Fig. 5Serum prolactin concentration profiles of 5 patients with a thyrotropinoma.

Negative_regulation (diminished) of Regulation (regularity) of PRL

2) Confidence 0.31 Published 2008 Journal Pituitary Section Body Doc Link PMC2712623 Disease Relevance 0.14 Pain Relevance 0

General Comments

This test has worked.